A golden goose gone: Why Glenmark Pharma's investors are unhappy with Nirma deal
Glenmark Pharma has hived off a 75 percent stake in Glenmark Life Sciences, which accounted for nearly 11 percent of its consolidated top line, and had a 20 percent EBITDA contribution, to clear debt
Source: moneycontrol.com